Contact
Privacy Policy

Copyright © DEEPNOID Inc. All rights reserved.

Back to list
Medical AI

DEEPNOID’s M4CXR Becomes the First Generative AI-Based Medical Device in Korea to Receive MFDS Innovative Medical Device Designation

November 28, 2025
DEEPNOID’s M4CXR Becomes the First Generative AI-Based Medical Device in Korea to Receive MFDS Innovative Medical Device Designation

DEEPNOID’s second Innovative Medical Device designation after DEEP:NEURO, confirming the innovation of its medical AI
“M4CXR is currently undergoing MFDS approval as a digital medical device and is expected to improve clinicians’ work efficiency”

DEEPNOID, one of Korea’s first-generation medical AI companies (CEO Woo Sik Choi), announced on November 28, 2025, that M4CXR has become the first generative AI-based medical device in Korea to receive Innovative Medical Device designation from the Ministry of Food and Drug Safety (MFDS). M4CXR was designated as an Innovative Medical Device in the advanced technology category (No. 119).
M4CXR is DEEPNOID’s in-house generative AI-based draft report generation solution for chest X-ray (CXR). It analyzes chest X-ray images taken to diagnose and screen for chest diseases, and within seconds produces AI-generated draft reports covering normal findings and 41+ abnormal findings related to chest diseases. Its clinical trial plan (IND) was approved in August 2025. As of November 2025, DEEPNOID had completed the clinical trial and was going through the MFDS approval process.
Innovative Medical Device designation is granted to medical devices that are expected to offer significantly improved safety or effectiveness compared with existing devices. This can come from applying advanced, technology-intensive innovations that evolve rapidly, or from improving how a device is used. Under the Act on Nurturing the Medical Device Industry and Supporting Innovative Medical Devices, designated products are eligible for institutional benefits during the approval process, including priority and phased review and customized technical consultation.
DEEPNOID received its first Innovative Medical Device designation in 2023 for DEEP:NEURO, its AI solution for cerebrovascular disease diagnostic assistance. As an Innovative Medical Technology, DEEP:NEURO then obtained a non-reimbursable billing code under Korea’s National Health Insurance in 2024. With M4CXR, DEEPNOID has now received its second Innovative Medical Device designation, once again confirming the innovation of its medical AI solutions.
“It is very meaningful to us that M4CXR is the first generative AI-based medical device to be designated as an Innovative Medical Device,” said Woo Sik Choi, CEO of DEEPNOID. “Since we have already completed the clinical trial and are going through the approval process, we expect M4CXR to significantly improve clinicians’ work efficiency in clinical settings before long.”
With support from the AI Semiconductor Application Demonstration Support Program run by the National IT Industry Promotion Agency (NIPA), DEEPNOID recently completed a demonstration with FuriosaAI applying Korean-made neural processing units (NPUs) to M4CXR. Starting with M4CXR, DEEPNOID plans to expand beyond chest X-ray to other modalities such as CT and MRI, and to broaden the clinical application of its generative AI-based solutions to a wider range of diseases.

###